Patents by Inventor Manfred Husemann

Manfred Husemann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200246347
    Abstract: Protein-inhibitory substituted pyrrolopyridine derivatives of formula (I) in which X, Y, R1, R2, R3 and R4 are as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: June 7, 2018
    Publication date: August 6, 2020
    Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
    Inventors: Norbert SCHMEES, Bernd BUCHMANN, Anders Roland FRIBERG, Hans BRIEM, Manfred HUSEMANN, Ulf BOMER, Gabriele LEDER, Rafael CARRETERO, Detlef STOCKIGT, Rienk OFFRINGA
  • Publication number: 20200199083
    Abstract: The present invention covers 4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-7-carboxamide compounds of general formula (I): in which R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5 and X are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: August 9, 2018
    Publication date: June 25, 2020
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Jörg WEISKE, Carlo STRESEMANN, Stefan Nikolaus GRADL, Ulrike RÖHN, Clara CHRIST, Holger STEUBER, Manfred HUSEMANN, Norbert SCHMEES, Kai THEDE, Stephan SIEGEL, Antonius TER LAAK
  • Publication number: 20190031773
    Abstract: The present invention is related to an antagonist of PYCR1 for the treatment and/or prevention of a neoplastic disease.
    Type: Application
    Filed: May 23, 2018
    Publication date: January 31, 2019
    Inventors: Sylvia GRÜNEWALD, Michael STECKEL, Manfred HUSEMANN, Hanna MEYER, Weiping HAN, Zhaobing DING
  • Patent number: 7842809
    Abstract: The invention relates to pyrazolopyridines according to the general formula (I): and salts thereof, to pharmaceutical compositions comprising said pyrazolopyridines and to a method of preparing said pyrazolopyridines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with angiopoietin and therefore influence Tie2 signalling.
    Type: Grant
    Filed: January 23, 2006
    Date of Patent: November 30, 2010
    Assignee: Bayer Schering Pharma AG
    Inventors: Wolfgang Schwede, Hans Briem, Hermann Kuenzer, Manfred Husemann, Georg Kettschau, Martina Schaefer, Antonius Ter Laak, Karl-Heinz Thierauch, Stuart James Ince
  • Patent number: 7750000
    Abstract: The invention relates to novel inhibitors of kinases, and pharmaceutical compositions comprising them. The inhibitors are substituted imidazo[1,2b]pyridazines.
    Type: Grant
    Filed: September 1, 2006
    Date of Patent: July 6, 2010
    Assignee: Bayer Schering Pharma AG
    Inventors: Olaf Prien, Stuart James Ince, Knut Eis, Christoph Huwe, Ulrich Lücking, Rolf Jautelat, Ulrich Zügel, Judith Günther, Benjamin Bader, Manfred Husemann, Karina Schuck
  • Publication number: 20080039455
    Abstract: The invention relates to pyrazolopyrimidines according to the general formula (I): and salts thereof, to pharmaceutical compositions comprising said pyrazolopyrimidines and to a method of preparing said pyrazolopyrimidines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment or prophylaxis of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth
    Type: Application
    Filed: June 20, 2007
    Publication date: February 14, 2008
    Inventors: Stuart Ince, Olaf Prien, Shoufu Lu, Hongyi Yu, Manfred Husemann, Karina Schuck
  • Publication number: 20070093490
    Abstract: The invention relates to novel inhibitors of kinases, methods for preparing such inhibitors, intermediates for the preparation of such inhibitors and uses of such inhibitors.
    Type: Application
    Filed: September 1, 2006
    Publication date: April 26, 2007
    Inventors: Olaf Prien, Stuart Ince, Knut Eis, Christoph Huwe, Ulrich Lucking, Rolf Jautelat, Ulrich Zugel, Judith Gunther, Benjamin Bader, Manfred Husemann, Karina Schuck
  • Publication number: 20060252782
    Abstract: The invention relates to macrocyctic sulfoximines of the general Formula I: wherein A, X, Y, R1, R2 and R3 have the meaning as given in the specification and the claims, and to salts thereof; to pharmaceutical compositions comprising the macrocyclic sulfoximines, and to a method of preparing the macrocyclic sulfoximines, as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with angiopoietin and therefore influence Tie2 signalling.
    Type: Application
    Filed: April 7, 2006
    Publication date: November 9, 2006
    Inventors: Ulrich Luecking, Georg Kettschau, Hans Briem, Wolfgang Schwede, Martina Schaefer, Karl-Heinz Thierauch, Manfred Husemann
  • Publication number: 20060252754
    Abstract: The invention relates to pyrazolopyridines according to the general formula (I): and salts thereof, to pharmaceutical compositions comprising said pyrazolopyridines and to a method of preparing said pyrazolopyridines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with angiopoietin and therefore influence Tie2 signalling.
    Type: Application
    Filed: January 23, 2006
    Publication date: November 9, 2006
    Inventors: Wolfgang Schwede, Hans Briem, Hermann Kuenzer, Manfred Husemann, Georg Kettschau, Martina Schaefer, Antonius Ter Laak, Karl-Heinz Thierauch, Stuart Ince
  • Publication number: 20060194823
    Abstract: The invention relates to sulfonamido-macrocycles according to the general Formula I and the salts thereof, to pharmaceutical compositions comprising the sulfonamido-macrocycles and to a method of preparing the sulfonamido-macrocycles as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with angiopoietin and therefore influence Tie2 signalling. wherein R1, R2, R4, A, X, Y, Z and m have the meaning as given in the specification and the claims.
    Type: Application
    Filed: December 21, 2005
    Publication date: August 31, 2006
    Inventors: Georg Kettschau, Hans Briem, Ingo Hartung, Ulrich Luecking, Martina Schaefer, Karl-Heinz Thierauch, Wolfgang Schwede, Manfred Husemann
  • Publication number: 20060167030
    Abstract: The invention relates to sulfonamido-macrocycles according to the general Formula I and the salts thereof, to pharmaceutical compositions comprising the sulfonamido-macrocycles and to a method of preparing the sulfonamido-macrocycles as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with angiopoietin and therefore influence Tie2 signalling. wherein R1, R2 and R3 have the meaning as given in the specification and the claims.
    Type: Application
    Filed: December 21, 2005
    Publication date: July 27, 2006
    Inventors: Georg Kettschau, Hans Briem, Andreas Huth, Ulrich Luecking, Martina Schaefer, Karl-Heinz Thierauch, Wolfgang Schwede, Manfred Husemann